Heidelberg, Germany, November 9, 2016 -
Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at the Jefferies 2016 London Healthcare Conference on Wednesday, November 16, 2016 at 4:00 p.m. (GMT) in London.
A live webcast of the conference presentation can be accessed through the "Events" section on the "Media" page of the Affimed website at http://www.affimed.com/events.php . A replay of the presentation will be available from Affimed's website for 30 days following the conference.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com .
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: IR@affimed.com or firstname.lastname@example.org
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
Last updated on: 10/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.